MUC16 and neoplasm: Generation and validation of a bispecific tandem-linked single-chain variable fragment directed to the retained portion of MUC16/CA125 (ectodomain) has been previously described by our group22 and others.23 In the report by Yeku et al.,22 MUC16/CA125 bispecific engagers were more effective in combination with either anti-PD-1 immune checkpoint inhibitors or anti-VEGF antibodies in tumor-bearing mice.